Skip to content
OpenCapital
Get started

Oruka Therapeutics, Inc. ORKA Investments - Gross Unrealized Losses

Investments - Gross Unrealized Losses at other companies

Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
——

Other financials

Income statement

See full
Revenue-—
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0×0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s investments - gross unrealized losses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s investments - gross unrealized losses?
Oruka Therapeutics, Inc. (ORKA) reported investments - gross unrealized losses of $348.72M in Q1 2026.
How has Oruka Therapeutics, Inc.'s investments - gross unrealized losses changed year-over-year?
Oruka Therapeutics, Inc.'s investments - gross unrealized losses increased by 58.6% year-over-year, from $219.8M to $348.72M.